Belite Bio's Tinlarebant Achieves 35.7% Reduction in Lesion Growth in First Successful Phase 3 Trial for Stargardt Disease
核心洞察
Belite Bio (搜索) announced positive topline results from the Phase 3 DRAGON trial of Tinlarebant, marking the first successful pivotal study in Stargardt disease type 1 (搜索) patients.
The oral therapy demonstrated a statistically significant 35.7% reduction in lesion growth rate compared to placebo over 24 months in 104 patients aged 12-20 years.
Tinlarebant was well tolerated with mild ocular side effects, and the company plans to file a new drug application with the FDA in the first half of 2026.
Belite Bio (搜索) announced positive topline results from its global Phase 3 DRAGON trial evaluating Tinlarebant, representing the first successful pivotal study conducted in patients with Stargardt disease type 1 (搜索) (STGD1 (搜索)). The oral therapy achieved a statistically significant 35.7% reduction in lesion growth rate compared to placebo, marking a potential breakthrough for a progressive eye disorder that currently has no approved treatments worldwide.
Trial Design and Patient Population
The DRAGON trial was a 24-month, randomized, placebo-controlled study that enrolled 104 patients aged between 12 and 20 years with Stargardt disease type 1 (搜索). All participants had at least one mutation identified in the ABCA4 (搜索) gene, an atrophic lesion size within three disc areas (7.62 mm²), and best corrected visual acuity of 20/200 or better.
Primary Endpoint Achievement
Tinlarebant achieved the study's primary endpoint by demonstrating a reduction in lesion growth rate of 35.7% versus placebo (P = .0033) as measured by retinal imaging. A post-hoc analysis showed that the treatment effect remained consistent (P < .0001). Researchers also observed a 33.6% reduction in lesion growth in the fellow eye.
The therapy additionally helped slow decreased autofluorescence lesion growth in the study eye (33.7%, P = .027) and fellow eye (32.7%, P = 0.017). The 5 mg dose reduced retinal binding protein 4 (RBP4 (搜索)) levels by a mean of 80% compared with baseline, and RBP4 levels returned to 84% of baseline at the study's conclusion.
Mechanism of Action and Clinical Significance
Tinlarebant is a novel oral therapy designed to reduce the accumulation of vitamin A-based toxins known as bisretinoids that cause retinal disease in STGD1 (搜索). The drug works by reducing and maintaining levels of serum retinol-binding protein 4 (搜索) (RBP4 (搜索)), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, Tinlarebant reduces the formation of bisretinoids.
"For a progressive disease with no current treatment options, gaining those extra years of better function is highly meaningful," said Hendrik Scholl, MD, Belite Bio (搜索)'s chief medical officer. "For patients, that could mean more years of being able to read, recognize faces and participate fully in school or work. For eye care providers, having a therapy that targets the underlying biology of the disease would represent a meaningful shift in how Stargardt is managed today."
Safety Profile
The drug was well tolerated throughout the trial. There were four drug discontinuations related to treatment, with no drug or trial discontinuations due to non-ocular adverse events. The most common drug-related ocular adverse event was xanthopsia, which along with delayed dark adaptation and night vision impairment was mild and most cases were resolved during the trial.
Regulatory Status and Next Steps
Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the US, and Orphan Drug Designation in the US, Europe, and Japan for the treatment of STGD1 (搜索). The drug has also obtained breakthrough therapy designation from the FDA.
Belite Bio (搜索) plans to file a new drug application with the FDA in the first half of 2026. The trial results reinforce the drug's potential as the company prepares to advance through the regulatory process.
Disease Background
Stargardt disease (搜索) stems from a hereditary anomaly in the ABCA4 (搜索) gene, manifesting when both copies of this gene carry mutations. This genetic defect leads to the accumulation of lipofuscin, a metabolic waste product, within the retina. The condition typically causes vision loss beginning in childhood or early adulthood, with severity varying widely among individuals due to the diverse spectrum of mutations within the ABCA4 gene.